Drug intelligence / Profile preview

MIIP-E1

Development stage: Preclinical
Lead developer: Lactea Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

MIIP-E1 is a natural peroxidase enzyme being developed by Lactea Therapeutics as part of its Multifunctional Innate Immune Protein (MIIP) portfolio. Derived from the innate immune system, MIIP-E1 is a protein biologic designed to leverage the oxidative and antimicrobial properties of peroxidases. While specific indications for MIIP-E1 have not been publicly disclosed, the MIIP platform generally targets wound care, biofilm infections, and the decontamination of chemical or antimicrobial agents. The development of MIIP-E1 is supported by collaborations with Johns Hopkins University and Brigham Young University (BYU).

Other names: Multifunctional Innate Immune Protein E1

Targets

LPO (Lactoperoxidase)

Beyond the preview

Go deeper on MIIP-E1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIIP-E1.

Explore the full profile